Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Keratosis, Actinic 37Melanosis 3Carcinoma, Basal Cell 3Warts 2Keratosis, Seborrheic 1Keratosis 1Facies 1Condylomata Acuminata 1Carcinoma, Squamous Cell 1Carcinoma 1Bowen's Disease 1

Interventions

Cryotherapy 11resiquimod 6Cantharidin 5PRA1 protein, Candida albicans 4Tuberculin 3Salicylic Acid 3Cholecalciferol 3plerixafor 2VP-102 2Solutions 2Sodium Chloride 2Saline Solution 2Photochemotherapy 2Percutaneous Collagen Induction 2N-phenylacetoaminomethylene-DL-p-nitrophenylalanine 2Measles-Mumps-Rubella Vaccine 2Lasers 2Hydrogen Peroxide 2Human Papillomavirus Recombinant Vaccine nonavalent 23-ingenyl angelate 22-Propanol 2methyl 5-aminolevulinate 1lactic acid, salicylic acid drug combination 1human papillomavirus vaccine, L1 type 16, 18 1green tea extract polyphenone E 1gluconic acid 1ethyl pyruvate 1compound W 1ammonium trichloro(dioxoethylene-O,O'-)tellurate 1Zinc Sulfate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Warts × 3-ingenyl angelate × Clear all
NCT02748902 2017-07-17

Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.

TCR Medical Corporation

Phase 1 Completed
16 enrolled

Warts

NCT00546611 2016-01-28

The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)

Peplin

Phase 1 Withdrawn

Warts

Data powered by HemOnc (CC BY 4.0) Colophon âš¡